Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade
Source
CAS 152923-56-3
Species
Humanized
Molecular weight
143kDa
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Daclizumab,BIIB019,DAC HYP,IL2RA,anti-IL2RA
Reference
PX-TA1038
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1-kappa
Clonality
Monoclonal Antibody
Description of Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade
General information on Anti-IL2RA(Homo sapiens) (Daclizumab) Monoclonal Antibody
Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively.
Reviews
There are no reviews yet.